EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Multicenter Study of Hyperpolarized Xenon Magnetic Resonance Imaging in Children with Cystic Fibrosis Following Initiation of Cystic Fibrosis Transmembrane Regulator Modulator Therapy (HyPOINT)

Felix A Ratjen, Sanja Stanojevic, Samal Munidasa, David Roach, Jaime Mata, Deborah K Froh, Brandon Zanette, Giles Santyr, Sean B Fain, Michael J Rock, Laura L Walkup iD, Jason C Woods

Annals of the American Thoracic Society · 2025

DOI: 10.1513/annalsats.202501-028oc ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Annals of the American Thoracic Society, 2025. Verfasst von Felix A Ratjen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Translational Medicine Program, Division of Respiratory Medicine, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Cystic Fibrosis, Magnetic Resonance Imaging, Benzodioxoles, Xenon Isotopes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Cystic Fibrosis Foundation, NCATS NIH HHS, National Center for Advancing Translational Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale

Elexacaftor/tezacaftor/ivacaftor (ETI) has significantly improved lung function in people with cystic fibrosis (CF), prompting the need for outcome measures that can detect mild disease. In this new era of CFTR (CF transmembrane regulator) modulator therapy, more sensitive endpoints are required to evaluate the progression of early lung disease and to determine the efficacy of new CF therapies. Before the availability of highly effective therapies, xenon-129 magnetic resonance imaging (MRI) was shown to be more sensitive to regional ventilation changes compared with spirometry.

Objectives

To evaluate the longitudinal changes in pulmonary function and Xe MRI outcomes after treatment with ETI in children and young people with CF.

Methods

Lung function was assessed longitudinally at baseline and 1, 6, and 12 months after ETI treatment initiation in children and young people with CF between the ages of 6 and 18 years at four study sites. Ventilation defect percentage (VDP), reader defect percentage (RDP), lung clearance index (LCI) and forced expiratory volume in 1 second (FEV1) were reported.

Results

A total of 28 participants were enrolled; 25 completed at least baseline and one-month measurements. All four measures (RDP, VDP, LCI, and FEV1) improved at one month after ETI initiation, with mean (standard deviation) absolute changes of −1.2 (1.7) in LCI, 6.9 (12.3) in FEV1 % predicted, −4.3 (4.8) in VDP, and −7.8 (9.6) in RDP. Xe MRI outcomes (RDP and VDP) showed the largest relative treatment effects, with mean relative improvements of 43% and 72%, respectively. One-third of participants (8 of 25) had improvements in VDP and RDP but did not show improvements in FEV1.

Conclusions

Xe MRI captures sustained ventilation improvements after ETI initiation. Xe MRI metrics may provide a suitable endpoint for future interventional trials, particularly for people with CF with mild lung disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisMagnetic Resonance ImagingBenzodioxolesXenon IsotopesAminophenolsQuinolonesLungIndolesHumansChildMaleFemaleAdolescentDrug CombinationsForced Expiratory VolumeRespiratory Function TestsPyrrolidinesLongitudinal StudiesPyridines

Stichwörter der Autor:innen

CFTR modulatorhyperpolarized 129Xemagnetic resonance imagingmulticenterventilation defect percentage

Substanzen

BenzodioxolesXenon IsotopesAminophenolsQuinolonesIndolesDrug Combinationstezacaftor, ivacaftor drug combinationPyrrolidinesXenon-129tezacaftor

Autor:innen und Institutionen

  • Translational Medicine Program, Division of Respiratory Medicine, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
  • Department of Community Health and Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada.
  • Center for Pulmonary Imaging Research, Division of Pulmonary Medicine.
  • Department of Radiology.
  • Department of Medical Imaging, and.
  • Department of Pediatrics, University of Virginia, Charlottesville, Virginia.

ORCID-Profile: Laura L Walkup

Förderung

  • Cystic Fibrosis Foundation
  • NCATS NIH HHS
  • National Center for Advancing Translational Sciences

Zitieren

APA

Ratjen, F. A., Stanojevic, S., Munidasa, S., Roach, D., Mata, J., Froh, D. K., Zanette, B., Santyr, G., Fain, S. B., Rock, M. J., Walkup, L. L., & Woods, J. C. (2025). Multicenter Study of Hyperpolarized Xenon Magnetic Resonance Imaging in Children with Cystic Fibrosis Following Initiation of Cystic Fibrosis Transmembrane Regulator Modulator Therapy (HyPOINT). Annals of the American Thoracic Society. https://doi.org/10.1513/annalsats.202501-028oc

Vancouver

Ratjen FA, Stanojevic S, Munidasa S, Roach D, Mata J, Froh DK, et al. Multicenter Study of Hyperpolarized Xenon Magnetic Resonance Imaging in Children with Cystic Fibrosis Following Initiation of Cystic Fibrosis Transmembrane Regulator Modulator Therapy (HyPOINT). Annals of the American Thoracic Society. 2025. doi:10.1513/annalsats.202501-028oc

BibTeX
@article{Ratjen2025,
  author = {Ratjen, Felix A and Stanojevic, Sanja and Munidasa, Samal and Roach, David and Mata, Jaime and Froh, Deborah K and Zanette, Brandon and Santyr, Giles and Fain, Sean B and Rock, Michael J and Walkup, Laura L and Woods, Jason C},
  title = {Multicenter Study of Hyperpolarized Xenon Magnetic Resonance Imaging in Children with Cystic Fibrosis Following Initiation of Cystic Fibrosis Transmembrane Regulator Modulator Therapy (HyPOINT)},
  journal = {Annals of the American Thoracic Society},
  year = {2025},
  doi = {10.1513/annalsats.202501-028oc}
}
Kostenlos starten →